Navigation Links
Marcadia and Lilly Sign Development, License Agreement for Novel Glucagon Program in Severe Hypoglycemia
Date:6/28/2010

INDIANAPOLIS, June 28 /PRNewswire-FirstCall/ -- Marcadia Biotech, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the companies have signed a development and exclusive license agreement for Marcadia's short-acting glucagon program, covering glucagon analogs that may provide greater convenience and ease-of-use than the current recombinant glucagon for the treatment of severe hypoglycemia. The program includes MAR531, a glucagon analog that is in preclinical development at Marcadia, as well as related backup compounds.

Under the terms of the agreement, Marcadia will continue to oversee development of the compound through regulatory approval in the U.S., while Lilly will be responsible for obtaining regulatory approval in countries outside the U.S. and for commercialization worldwide.  Financial terms of the collaboration were not disclosed.

"Glucagon is an important therapeutic for people with diabetes to treat an episode of severe hypoglycemia, but the currently marketed products require  reconstitution from a lyophilized (powder) form before administering an injection," said Enrique Conterno, president of Lilly Diabetes. "A new glucagon therapy that can be stored in solution form at room temperature and supplied in a convenient injection device could be an important advance for patients."

Fritz French, chief executive officer of Marcadia, added, "Lilly's long experience and expertise in diabetes, including its position as the market leader in the glucagon emergency kit space, was an important consideration for Marcadia. Their capabilities, combined with our unique peptide chemistry, which has been instrumental to all of our peptide discovery and development programs, should maximize the potential for this compound to benefit patients suffering from diabetes."

The companies plan to develop the short-acting glucagon analog to be supplied and stored in a single-use auto-injection "pen" device. MAR531 and related backup compounds were discovered through Marcadia's sponsored research agreement with Indiana University, Bloomington.

About Eli Lilly and Company

Eli Lilly and Company, a leading innovation-driven company, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Information about Lilly is available at www.lilly.com.    C-LLY

About Marcadia Biotech

Marcadia Biotech is a biopharmaceutical company focused on developing a broad portfolio of drug candidates for the treatment of diabetes and obesity. Using proprietary peptide chemistry, Marcadia seeks to develop candidates with unprecedented performance in key metabolic hormone pathways. Separately, the company is also developing a dual agonist of GIP and GLP-1 for the treatment of diabetes (MAR701) and a set of novel peptides that target GLP-1 biology. Founded in 2006, Marcadia is based in Carmel, Ind. For more information, visit http://www.marcadiabiotech.com.

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company; Marcadia Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes
2. Lilly Declares Third-Quarter 2010 Dividend
3. Lilly Presents New Data in Advanced Melanoma - A Difficult-To-Treat Cancer That Causes Majority of Skin Cancer Deaths
4. Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations
5. Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux
6. Lillys Online, Interactive Health Education Program Receives Two Web Awards
7. Lilly Reports Fourth-Quarter and Full-Year 2009 Results
8. Lilly Confirms Date and Conference Call For Fourth-Quarter and Full-Year 2009 Financial Results Announcement
9. Lilly CEO Stresses Human Element in Driving Medical Innovation
10. Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
11. PDL BioPharma Announces New Licensing Agreement With Eli Lilly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... -- AVACEN Medical , Inc. (AVACEN) announced that Frost ... Product Innovation Award for Its fibromyalgia pain management device. ... device market research by Frost & Sullivan,s industry experts. ... relief product, the AVACEN 100, offers a safe and effective ... ...
(Date:10/12/2017)... Oct. 12, 2017 West Pharmaceutical Services, ... solutions for injectable drug administration, today announced that it ... opens on Thursday, October 26, 2017, and will follow ... business expectations at 9:00 a.m. Eastern Time. To participate ... (International). The conference ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... ... 2017 , ... First Healthcare Compliance (FHC), an industry leader ... range of technology and learning solutions at the 68th Annual American Healthcare Association ... held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, Nevada. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
Breaking Medicine News(10 mins):